Prodrugs pp 1111-1124 | Cite as

Safety Assessment of Prodrugs

  • Scott J. Grossman
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)


An important aspect of drug development is the overall safety assessment process. Safety assessment considers the range of potential risks that patients may encounter, through detailed studies of preclinical species. This process guides the course of clinical development and serves as an important consideration in the ultimate benefit/risk evaluation by the sponsor and international regulatory agencies. Safety assessment is increasingly vast in scale and scope. Thus, for the purposes of this chapter, no attempt will be made to teach the process of safety assessment. The purpose of this chapter is to familiarize the reader with the various aspects of prodrugs requiring special consideration during this critical part of drug development.


Parent Drug Risk Evaluation Safety Assessment Hydroxy Acid Good Laboratory Practice 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Buchwald P. Structure-metabolism Relationships: Steric Effects and the Enzymatic Hydrolysis of Carboxylic Esters: Mini Rev. Med Chem 2001; 1:101–111Google Scholar
  2. Buchwald P, and Bodor N. Physicochemical Aspects of the Enzymatic Hydrolysis of Carboxylic Esters. Pharmazie 2002; 57:87–93PubMedGoogle Scholar
  3. Caldwell J. Problems and Opportunities in Toxicity Testing Arising from Species Differences in Xenobiotic Metabolism. Toxicol Lett 1992; 9:64–65Google Scholar
  4. Cashman JR, Perotti BY, Berkman CE, and Lin J. Pharmacokinetics and Molecular Detoxication: Environ Health Perspect 1996; 1:23–40CrossRefGoogle Scholar
  5. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, and Baillie TA. Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization. Drug Metab Dispos 2002; 30:505–512PubMedCrossRefGoogle Scholar
  6. Vickers S, Duncan KP, Vyas PH, Arison KB, Prakash SR, Ramjit HG, Pitzenberger SM, Stokker G, and Duggan DE. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990; 18:476–483PubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Scott J. Grossman
    • 1
  1. 1.Bristol-Myers Squibb Co.Princeton

Personalised recommendations